Skip to main content

Table 1 Baseline characteristics of the study participants

From: Plasma repressor element 1-silencing transcription factor levels are decreased in patients with Alzheimer's disease

Items

NC

(n = 89)

aMCI (n = 79)

AD dementia

(n = 84)

Age (y)

68.60 ± 9.28

69.16 ± 8.55

69.13. ± 8.54

Male (%)

63(54.78%)

45(47.37%)

43(43.88%)

Education(y)

13.07 ± 7.25

11.04 ± 3.17*

10.83 ± 4.48*

Neuropsychological tests

  n

89

79

84

  MMSE

27.96 ± 1.25

26.71 ± 1.71*

17.00 ± 5.77**

  ISR

25.58 ± 10.61

12.10 ± 6.40**

2.34 ± 2.75**

  DSR

23.26 ± 11.73

6.03 ± 4.20**

0.60 ± 1.67**

  CDT

3.95 ± 0.22

3.78 ± 0.50

2.41 ± 1.33**

  TMT-A

67.74 ± 27.23

71.26 ± 29.01

122.07 ± 33.11**

  CDR-SB

0.78 ± 0.98

1.42 ± 1.20*

6.31 ± 3.12**

  ADL

14.08 ± 0.28

14.28 ± 0.45*

23.16 ± 6.19*

MRI visual rating scale

  n

77

52

55

  MTA-right

0.62 ± 0.76

0.98 ± 0.92*

1.76 ± 1.02**

  MTA-left

0.79 ± 0.86

0.96 ± 0.91

1.89 ± 1.05**

  GCA

0.74 ± 0.75

1.11 ± 0.91*

0.97 ± 0.86

  PA

0.62 ± 0.66

0.94 ± 0.72**

1.12 ± 0.66**

  MTAi-right

1.97 ± 1.48

2.71 ± 1.46**

3.47 ± 1.71**

  MTAi-left

1.71 ± 1.49

2.35 ± 1.37*

3.42 ± 1.58

  1. NC normal control, aMCI amnestic mild cognitive impairment, AD Alzheimer’s disease, MMSE Mini Mental State Examination, ISR Instant Story Recall, DSR Delayed Story Recall, CDT Clock Drawing Test, TMT-A Trail Making Test A, CDR-SB Clinical Dementia Rating Sum of Boxes, ADL Activities of Daily Living
  2. * p < 0.05 for the AD dementia or aMCI group vs the NC group
  3. ** p < 0.01 for the AD dementia or aMCI group vs the NC group
  4. p < 0.05 for the AD dementia vs the aMCI group
  5. p<0.01 for AD dementia vs the aMCI group
  6. MRI magnetic resonance imaging, MTA medial temporal lobe atrophy scale, GCA global cortical atrophy scale, PA posterior atrophy, MTAi medial temporal lobe atrophy index (medial temporal lobe region − the parenchyma within the medial temporal region) × 10/body of the ipsilateral lateral ventricle